Incyte Reports 2018 Fourth Quarter and Year-End Financial Results, Provides 2019 Financial Guidance and Provides Updates on Key Clinical Programs

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Incyte Reports 2018 Fourth Quarter and Year-End Financial Results, Provides 2019 Financial Guidance and Provides Updates on Key Clinical Programs

Incyte (INCY) PT Raised to $89 at RBC Capital

February 15, 2019 7:16 AM EST

RBC Capital analyst Brian Abrahams raised the price target on Incyte (NASDAQ: INCY) to $89.00 (from $81.00) while maintaining a Outperform rating.

The analyst commented, "Coming off of a solid quarter for sales and guidance, we see the potential for some additional appreciation in INCYwith... More

Incyte (INCY) PT Raised to $100 at Raymond James

February 15, 2019 7:10 AM EST

Raymond James analyst Reni Benjamin raised the price target on Incyte (NASDAQ: INCY) to $100.00 (from $85.00) while maintaining a Strong Buy rating following results and guidance.

Benjamin said key takeaways include: 1) The Jakafi franchise remains solid with 2018 sales at $1.39 billion; 2) 2019 guidance is for Jakafi to... More

Incyte (INCY) Misses Q4 EPS by 7c

February 14, 2019 7:04 AM EST

Incyte (NASDAQ: INCY) reported Q4 EPS of $0.40, $0.07 worse than the analyst estimate of $0.47. Revenue for the quarter came in at $468 million versus the consensus estimate of $485.8 million.

2019 Financial... More